PSC AN11 at National Aeronautics and Space Administration

Procurement patterns and delivery vehicles for R&D - Biomedical: mRNA Vaccines and Therapeutic Platforms at National Aeronautics and Space Administration (NASA).

Procurement Overview

Verified SAM.gov & FPDS Data

The National Aeronautics and Space Administration (NASA) obligates an estimated $4.80B annually under PSC AN11 (R&D - Biomedical: mRNA Vaccines and Therapeutic Platforms), prioritizing certified prime vendors and specialized task order vehicles.

•Agency Spend: $4.80B

•National PSC Spend: $21.80B

•Agency Share: ~22% of national total